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0-Year Follow-Up of the First Cypher Stent
mplanted in Human
n Invasive Evaluation With Angiography, Intravascular Ultrasound,
nd Optical Coherence Tomography
. Eduardo Sousa, MD, PHD, J. Ribamar Costa, JR, MD, Alexandre Abizaid, MD, PHD
ão Paulo, Brazilh
i
s
d
iograp75-year-old woman presented to our service
ith stable angina (Canadian Cardiovascular Soci-
ty III) and a positive treadmill test in December
999. She had a previous history of systemic
rom the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
Figure 1. Procedure and Protocol Invasive Follow-Up
(A) Presence of severe obstruction in the proximal segment of the
implant of a 3.5  18 mm Cypher sirolimus-eluting stent; (C) 4-mo
24-month follow-up angiography; and (F) 48-month follow-up anganuscript received December 17, 2009, accepted December 24, 2009.ypertension, hyperlipidemia, and hypothyroid-
sm. Her coronary angiography showed significant
ingle de novo lesion in the proximal left anterior
escending artery (Fig. 1A). After having signed
nterior descending coronary artery; (B) ﬁnal result after the
llow-up angiography; (D) 12-month follow-up angiography; (E)
hy. No sign of signiﬁcant late loss was observed along the years.left a
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557he informed consent, she became the first person ever to
eceive the slow-release (28-day drug release) sirolimus-
luting stent that later became the commercially approved
ypher stent (Cordis Corporation, Johnson & Johnson,
arren, New Jersey) (Fig. 1B).
She was discharged with a regimen of aspirin (110
g/day), ticlopidina (500 mg b.i.d.), atenolol (100 mg/day),
imvastatin (40 mg/day), and levothyroxine (50 g/day).
ual antiplatelet therapy was maintained for 2 months only.
he underwent invasive follow-ups at 4, 12, 24, and 48
onths (1–4) (Figs. 1C to 1F), per protocol. Since the
aseline procedure she has remained asymptomatic with
everal negative stress tests along the 9 years of clinical
ollow-up.
During the 2009 meeting of the Latin America Society of
nterventional Cardiology (SOLACI, Rio de Janeiro, Bra-
il), she kindly agreed to undergo an invasive follow-up with
ngiography (Figs. 2A and 2B), intravascular ultrasound
IVUS) (Fig. 2C, Online Video 1), and optical coherence
omography (OCT) (Fig. 2D, Online Video 2) during a live
ransmission session, which became the longest-term avail-
Figure 2. 10-Year Invasive Follow-Up
(A, B) Angiography in 2 different projections showing the maintenance of the
angiographic result (Online Video 1). (D) Optical coherence tomography image
tion (Online Video 2).ble invasive follow-up for the Cypher stent.
1The IVUS examination was performed with a 40-MHz
tlantis SR Pro catheter (Boston Scientific, Natick, Mas-
achusetts), whereas OCT images were obtained with the
mageWire system (LightLab Imaging, Westford, Massa-
husetts). The main findings of this latest follow-up include
sustained antiproliferative effect of the Cypher sirolimus-
luting stent, by both angiography (in-stent late lumen loss
f 0.10 mm at 9 months as compared to 0.10 mm at 4
onths, 0.11 mm at 12 months, 0.12 mm at 24 months,
nd 0.11 at 48 months) and IVUS examination (in-stent
ercentage of obstruction of 1% at 4 months and 1, 2, 4, and
years). Ten-year OCT assessment revealed a complete
overage of 90% of the analyzed struts.
eprint requests and correspondence: Dr. J. Eduardo Sousa, Av
r. Dante Pazzanese, 500 Ibirapuera, São Paulo-SP 04012-180,
razil. E-mail: jesousa@uol.com.br.
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